On May 28, 2026 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago, Illinois taking place May 29 – June 2, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Key data that will be presented include:
Abstract #3077 validating the use of Guardant360 Liquid CDx as a companion diagnostic for therapy selection and comprehensive pan-cancer tumor profiling in routine oncology practice. Findings led to recent FDA approval of the IVD assay, marking the world’s largest FDA-approved liquid biopsy panel, demonstrating how incorporating both genomic and epigenomic signals for variant detection produces strong analytical sensitivity, accuracy, and specificity across clinically relevant alterations.
Abstract #3070 revealing the potential of Guardant360 Liquid in expanding access to targeted ALK inhibitor therapy and getting the right treatment to lung patients faster. Demonstrating advanced detection missed by standard genomic methods, the analysis demonstrated improved detection of actionable ALK fusions in non-small cell lung cancer (NSCLC) while maintaining high specificity by identifying additional ALK fusion-positive cases.
Abstract #TPS10632 evaluating longitudinal performance of the Shield blood test for primary colorectal cancer screening in its intended use population, building off the strong performance in the prospective, observational ECLIPSE study that led to FDA approval.
"Our presence at this year’s ASCO (Free ASCO Whitepaper) reflects the power of liquid biopsy tests to provide oncologists with actionable insights to more effectively treat patients in a faster amount of time," said Helmy Eltoukhy, Guardant Health chairman and co-CEO. "Guardant’s Smart Platform, an AI-enabled multiomic technology platform behind our next generation of cancer tests, is fueling the entire portfolio and supporting new clinical applications across the cancer care continuum."
Key Guardant Health and collaborator presentations at ASCO (Free ASCO Whitepaper) 2026
Presentation
Title
Time / Location
8502
Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study
May 29, 2026 / 1:00 – 4:00 PM CDT
3525 / 279
A deep learning approach to quantify tumor microenvironment features associated with postoperative ctDNA status and outcomes in a phase III FOLFOX-based adjuvant colon cancer trial (N0147; Alliance)
May 30, 2026 / 9:00 AM – 12:00 PM CDT
3546 / 313
A multicenter single-arm phase II trial evaluating the safety and efficacy of panitumumab and irinotecan in NeoRAS wild-type metastatic colorectal cancer patients (C-PROWESS)
May 30, 2026 / 9:00 AM – 12:00 PM CDT
3572 / 339
Circulating tumor DNA (ctDNA) tumor fraction (TF) dynamics to refine progression-free survival and radiographic response during anti-EGFR rechallenge in metastatic colorectal cancer
May 30, 2026 / 9:00 AM – 12:00 PM CDT
3659 / 426
Evaluation of circulating tumor DNA (ctDNA) burden, detected mutations and clinical outcomes in metastatic colorectal cancer (mCRC) using real-world data (RWD)
May 30, 2026 / 9:00 AM – 12:00 PM CDT
4050 / 33
Molecular circulating tumor DNA (ctDNA) profiling from patients (pts) treated with zanidatamab + chemotherapy (CT) in first-line (1L) HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA)
May 30, 2026 / 9:00 AM – 12:00 PM CDT
4159 / 142
First-line GemCis ± immunotherapy vs FGFR inhibition in ctDNA-detected FGFR2 fusion-positive advanced cholangiocarcinoma: a real-world analysis
May 30, 2026 / 9:00 AM – 12:00 PM CDT
4161 / 144
Real-world analysis of epigenomic molecular tumor-type prediction for biliary tract cancer in CUP
May 30, 2026 / 9:00 AM – 12:00 PM CDT
4238 / 221
Real-world outcomes in gastrointestinal cancer patients with targetable genomic alterations identified on serial liquid biopsy
May 30, 2026 / 9:00 AM – 12:00 PM CDT
3051 / 188
Tumor-of-origin prediction using methylation signals from plasma cell-free DNA (cfDNA): Real-world experience in Asia and the Middle East (AME)
May 30, 2026 / 1:30 – 4:30 PM CDT
3052 / 189
Tissue-free minimal residual disease evaluation and clinical utility in early breast cancer: a real-world study
May 30, 2026 / 1:30 – 4:30 PM CDT
3070 / 207
Cell-free DNA methylation profile-based fusion epigenotyping to enhance ALK fusion detection in NSCLC patients
May 30, 2026 / 1:30 – 4:30 PM CDT
3077 / 214
Analytical validation of a plasma-based cfDNA NGS assay (Guardant360 Liquid CDx) for comprehensive solid tumor profiling
May 30, 2026 / 1:30 – 4:30 PM CDT
3105 / 242
Phase II basket trial of brigatinib for ALK fusion–positive solid tumors: ALLBREAK trial (WJOG15221M)
May 30, 2026 / 1:30 – 4:30 PM CDT
1031 / 145
Concordance between liquid and tissue biopsy in participants with newly diagnosed recurrent breast cancer
June 1, 2026 / 1:30 – 4:30 PM CDT
1095 / 209
Liquid-based methylation profiling of molecular breast cancer subtypes (MBS) in hormone receptor positive (HR+) metastatic breast cancer (MBC) treated with CDK4/6 inhibitor (CDK4/6i)
June 1, 2026 / 1:30 – 4:30 PM CDT
The full abstracts for Guardant Health and a list of all abstracts being presented at ASCO (Free ASCO Whitepaper) 2026 can be found on the ASCO (Free ASCO Whitepaper) website.
About Guardant360 Liquid CDx
The largest FDA-approved liquid biopsy, Guardant360 Liquid CDx is the only FDA-approved liquid biopsy test integrating genomic and epigenomic data for comprehensive insights. Guardant360 Liquid CDx is approved as a companion diagnostic for multiple therapies in non-small cell lung cancer and colorectal cancer. It is also the only FDA-approved companion diagnostic for targeted therapy in advanced breast cancer patients with ESR1 mutations. The test is broadly covered by Medicare and commercial insurers, representing over 300 million lives.
About Guardant360 Liquid
Guardant360 Liquid is a blood-based test that analyzes tumor DNA fragments circulating in the blood (cfDNA) to identify genetic mutations in advanced solid tumors, helping oncologists find targeted therapies. It offers an alternative to tissue biopsies, providing comprehensive genomic profiling (CGP) to guide personalized treatment for a wide range of solid cancers including lung, breast, colorectal, and prostate cancer. Guardant360 Liquid is guideline-complete across all advanced solid tumors, and has been clinically validated in more than 1,500 publications and research abstracts.
About Guardant Reveal
Guardant Reveal is a tissue-free liquid biopsy test that detects minimal residual disease (MRD) and monitors recurrence in early-stage colorectal, breast, and lung cancers, helping oncologists guide treatment decisions. In addition to MRD detection, Reveal can be used for late-stage therapy response monitoring for patients with solid tumors. Guardant Reveal therapy response monitoring can be initiated at any time during a patient’s treatment journey, offering clinicians flexibility and actionable insights.
The first clinical-validation study of pan-cancer chemotherapy monitoring published in The Journal of Liquid Biopsy showed that Guardant Reveal predicts long-term patient benefit up to 18 months earlier than standard clinical measures.
About Shield
Shield is a methylation partitioning cell-free DNA (mp-cfDNA) non-invasive, blood-based screening test that detects alterations associated with colorectal cancer in the blood. It is intended as a screening test for individuals at average risk for the disease, age 45 or older, and is not intended for individuals at high risk for colorectal cancer. The Shield test can be considered in a manner similar to guideline-recommended non-invasive CRC screening options and can be completed during any healthcare visit. A positive Shield result raises concern for the presence of colorectal cancer or advanced adenoma and the patient should be referred for colonoscopy evaluation.
(Press release, Guardant Health, MAY 28, 2026, View Source [SID1234666170])